Risk Reducing Salpingo-Oophorectomy (RRSO) in BRCA Carriers

  • BRCA 1 carriers:
    • Are at increased risk of:
      • Breast
      • Ovarian
      • Prostate
      • Pancreatic cancer
      • Melanoma
  • RRSO is recommended between:
    • Ages 35 to 40 in BRCA 1
    • Ages 40 to 45 in BRCA2 carriers, or
      • When done having children
  • RRSO has been shown to reduce the risk of breast cancer:
    • In premenopausal women by about 50%
  • RRSO has also been shown to reduce the risk of ovarian cancer by 80%
  • In women who have not undergone RRSO, surveillance with CA 125 and pelvic ultrasound:
    • May be considered at the clinician’s discretion beginning ages 30 to 35
  • References
    • NCCN Guideline with NCCN Evidence Blocks™ – Breast Cancer Version 4.2024. National Comprehensive Cancer Network website. https://www.nccn.org/professionals/physician_gls/recently_updated.aspx. Accessed August 16, 2024.
    • Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87

Leave a comment